The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's

Wegovy, Ozempic added to list of drugs where the federal government will try winning discounts from manufacturers.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight-loss drugs — but says subjecting Wegovy to price controls is a bad move.